Alexion Pharmaceuticals
ALXN
ALXN was delisted on the 20th of July, 2021.
522 hedge funds and large institutions have $31.9B invested in Alexion Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 56 funds opening new positions, 182 increasing their positions, 210 reducing their positions, and 48 closing their positions.
17% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 48
6% more capital invested
Capital invested by funds: $30B → $31.9B (+$1.91B)
0% more funds holding
Funds holding: 521 → 522 (+1)
13% less funds holding in top 10
Funds holding in top 10: 15 → 13 (-2)
13% less repeat investments, than reductions
Existing positions increased: 182 | Existing positions reduced: 210
22% less call options, than puts
Call options by funds: $126M | Put options by funds: $160M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$395M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$393M |
| 3 |
Winslow Capital Management
Minneapolis,
Minnesota
|
+$81.1M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$80.3M |
| 5 |
Jennison Associates
New York
|
+$38.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Norges Bank
Oslo,
Norway
|
-$217M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$124M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$120M |
| 4 |
Millennium Management
New York
|
-$119M |
| 5 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
-$71.5M |
ALXN Hedge Fund Activity: Q3 2014 in Review
522 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q3 2014, worth a combined $31.9B — up 6.4% from $30B a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new ALXN positions and 48 closed out — a net gain of 8 holders — while 182 added to existing stakes and 210 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $395M. The largest seller was Norges Bank, cutting an estimated $217M.
- 522 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q3 2014, up from 521 in Q2 2014.
- Funds reported $31.9B of Alexion Pharmaceuticals stock for Q3 2014, up 6.4% quarter-over-quarter.
- 56 funds opened new Alexion Pharmaceuticals positions in Q3 2014 and 48 closed out, a net change of +8 holders.
- The largest Alexion Pharmaceuticals buyer in Q3 2014 was T. Rowe Price Associates, an estimated $395M added.
- The largest Alexion Pharmaceuticals seller in Q3 2014 was Norges Bank, an estimated $217M sold.
Based on aggregated 13F filings for Q3 2014.